ストックスクリーナーアプリを入手
4.62
0.00%
0.00
プレマーケット:
4.57
-0.05
-1.08%
Emergent Biosolutions Inc (EBS) 最新ニュース
Lobbying Update: $920,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Nasdaq
Emergent BioSolutions ($EBS) Is Paying a $40M Settlement to Investors — Here’s How to Get Your Share - TradingView
Institutional investors in Emergent BioSolutions Inc. (NYSE:EBS) see US$31m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Emergent BioSolutions launches stock repurchase program - MSN
Mile Marker Continues New Business Success With Growth-Oriented Brands - Yahoo Finance
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS - Business Wire
Emergent BioSolutions sets $50 million stock buyback plan By Investing.com - Investing.com South Africa
Emergent BioSolutions Authorizes $50 Million Stock Buyback Program - MarketScreener
Emergent BioSolutions Announces Repurchase Of Up To $50 Mln Stock, Pre-market Stock Up - Nasdaq
Emergent BioSolutions sets $50 million stock buyback plan - Investing.com
$50M Stock Buyback: Emergent BioSolutions Signals Strong Confidence in Turnaround Plan - Stock Titan
Q1 Earnings Estimate for EBS Issued By HC Wainwright - MarketBeat
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap (NYSE:EBS) - Seeking Alpha
SEC Form DEFA14A filed by Emergent BioSolutions Inc. - Quantisnow
Expert Outlook: Emergent BioSolutions Through The Eyes Of 5 Analysts - Benzinga
Benign Growth For Emergent BioSolutions Inc. (NYSE:EBS) Underpins Stock's 31% Plummet - simplywall.st
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - The Manila Times
Just Awarded: Emergent BioSolutions Grants Major 72,882 Share Package to Strategic New Hire - Stock Titan
Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues - Seeking Alpha
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg - The Manila Times
Breakthrough: New High-Dose Naloxone Spray Gets Health Canada Green Light as Overdose Crisis Persists - StockTitan
Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions - Medical Dialogues
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International - citybiz
Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc. - Equity Bulls
Emergent BioSolutions sells Baltimore facility to Syngene By Investing.com - Investing.com South Africa
Emergent BioSolutions Completes Sale of Baltimore-Bayview Facility to Syngene International - Marketscreener.com
Emergent BioSolutions sells Baltimore facility to Syngene - Investing.com India
Emergent Biosolutions finalizes sale of Baltimore-Bayview manufacturing site to Syngene International - Marketscreener.com
Emergent BioSolutions Strategic Win: $36.5M Facility Sale While Securing Future Production Rights - StockTitan
Emergent BioSolutions secures $27 million in MCM orders By Investing.com - Investing.com Australia
Emergent BioSolutions secures $27 million in MCM orders - Investing.com
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products - The Manila Times
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International - EIN News
Syngene Acquires First US Manufacturing Facility - Contract Pharma
India-based Syngene acquires its first US biologics site - Manufacturing Dive
Emergent BioSolutions to invest in Rocketvax for vaccine developments - MSN
Emergent BioSolutions to sell Baltimore-Bayview manufacturing site for $36.5M - MSN
Emergent signs financial investment agreement with Swiss Rockets - Yahoo
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs - The Manila Times
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by ... - The Bakersfield Californian
First OTC Narcan Program Targets High-Risk Construction Workers to Combat Overdose Crisis - StockTitan
Emergent BioSolutions director Zoon sells $57,300 in stock By Investing.com - Investing.com Australia
Emergent BioSolutions director Fowler sells $204,050 in stock By Investing.com - Investing.com Australia
Emergent BioSolutions director Fowler sells $204,050 in stock - Investing.com India
Emergent BioSolutions director Zoon sells $57,300 in stock - Investing.com
0.74%
0.80%
大文字化:
|
ボリューム (24 時間):